Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05574673
Other study ID # NSGO-CTU-HERO
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 1, 2022
Est. completion date December 1, 2028

Study information

Verified date May 2024
Source Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Contact Mansoor R Mirza, MD
Phone 004535459624
Email mansoor.raza.mirza@regionh.dk
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a prospective observational multi-country, multi-center study of a large real-world cohort of first line (1L) epithelial ovarian cancer patients, exposed to standard of care (SOC) treatment stratified according to BRCA1/2 and HRD status.


Description:

The overall objective of the study is to demonstrate the distribution of ovarian cancer by HRD and BRCA1/2 mutational status and further characterize sub-cohorts of long- and short-term responders. Additionally, to collect representative clinical samples for further translational analyses. The overall objective is separated by two distinct observational periods defined as Observational Period 1 (OP1) and Observational Period 2 (OP2): - OP1: From date of diagnosis to date of first response assessment following 1L chemotherapy, progression or death, whichever occurs first - OP2: From date of first response assessment following 1L chemotherapy to maximum 36 months following 1L chemotherapy, death or withdrawal of consent, whichever occurs first. Objective for Observational Period 1 (OP1) The objective for OP1 is to demonstrate the distribution of ovarian cancer patients with FIGO stage I-II BRCA1/2mut ovarian cancer, or stage III-IV ovarian cancer in cohorts of BRCA1/2, HRD (either BRCA1/2 mutation and/or genomic instability), HRP and HR-unknown patients. Objective for Observational Period 2 (OP2) The objective for OP2 is to further characterize sub-cohorts of short-term responders (progressing < 6 months following maintenance treatment) and long-term responders (progressing ≥ 32 months following maintenance treatment) in real-world cohorts of ovarian cancer patients. For FIGO stage I-II BRCA1/2mut or FIGO stage III-IV defined by HRD status determined by Myriad myChoice® CDx HRD test or non-Myriad local HRD test, and BRCA1/2 status. A total of 350 patients will be enrolled from hospitals in Denmark, Finland, Norway, and Sweden. Competitive enrollment will be applied. Eligible patients must have newly diagnosed histologically confirmed epithelial ovarian cancer: - FIGO stage I-II with a known BRCA1/2 mutation (germline/gBRCA or somatic /tBRCA) - FIGO stage III-IV of any histology of any histology.


Recruitment information / eligibility

Status Recruiting
Enrollment 350
Est. completion date December 1, 2028
Est. primary completion date December 1, 2028
Accepts healthy volunteers
Gender Female
Age group 18 Years to 100 Years
Eligibility Patients are eligible to be included in the study, if all the following inclusion criteria are met: - Patients with newly diagnosed histologically confirmed epithelial ovarian cancer: - FIGO stage I-II with a known BRCA1/2 mutation (germline/gBRCA or somatic/tBRCA) - FIGO stage III-IV of any histology - Women aged =18 years of age at the time of diagnosis - Patients intended for platinum-based chemotherapy treatment - Patients capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol - Patients consent to provide archival tumor tissue sample Patients are ineligible to be included in the study, if any of the exclusion criteria are met: - Non-epithelial ovarian cancer, borderline tumors, or mucinous histology - Patients with FIGO stage I-II, BRCAwt ovarian cancer

Study Design


Intervention

Other:
Standard of care
Patients receive standard of care treatment according to local and national guidelines

Locations

Country Name City State
Denmark Rigshospitalet København Ø Sjaelland

Sponsors (1)

Lead Sponsor Collaborator
Nordic Society of Gynaecological Oncology - Clinical Trials Unit

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Endpoint OP1 Frequency of surgical resection 36 months
Secondary Endpoints OP1 - 1.1 - First line anti-cancer treatment including outcome 36 months
Secondary Endpoints OP1 - 1.2 - +/- Residual disease following Primary Cytoreductive Surgery (P-CRS) 36 months
Secondary Endpoints OP1 - 1.3 - Overall Response Rate (ORR) 36 months
Secondary Endpoints OP1 - 1.4 - BRCA1/2 and HRD status 36 months
Secondary Endpoint OP2 - 2.1 - Number of patients receiving maintenance treatment or not 36 months
Secondary Endpoint OP2 - 2.2 - Progression-Free-Survival (PFS) at 6, 12, 24 and 32 months 36 months
See also
  Status Clinical Trial Phase
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Withdrawn NCT05201001 - APX005M in Patients With Recurrent Ovarian Cancer Phase 2
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05156892 - Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer Phase 1
Suspended NCT02432378 - Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines Phase 1/Phase 2
Recruiting NCT04533763 - Living WELL: A Web-Based Program for Ovarian Cancer Survivors N/A
Active, not recruiting NCT03371693 - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Completed NCT01936363 - Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer Phase 2
Completed NCT02019524 - Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients Phase 1
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Terminated NCT03146663 - NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer Phase 2